Cai et al. [41] demonstrated that sorafenib and AuNP–anti-miRNA-221 combination treatment exerts an anticancer effect on HCC via inhibiting miRNA-221/p27/DNMT1 signalling pathway. The gene discussed is DNMT1; the disease is hepatocellular carcinoma.